I was reading this article then this caught my attention.

Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar

Quote:

---

With little more than preclinical data and some initial dosing cohort insights available for review, Eli Lilly is making a $400 million-plus play to buy into an early-stage autoimmune drug at Nektar $NKTR that the pharma giant believes has megablockbuster potential.

Eli Lilly $LLY has agreed to acquire co-development rights on NKTR-358 — which was first dosed in a human in a Phase I study 4 months ago — for $150 million up front plus $250 million in milestones. Lilly will pick up 75% of the Phase II development costs and Nektar will have the opt-in rights on this drug on an indication-by-indication basis.

---

https://endpts.com/eli-lilly-buys-into-a-400m...om-nektar/

So $150M upfront payment for a Phase 1 drug with the potential to treat different autoimmune diseases. If only IPIX has a similar drug...